“Sjogren’s Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sjogren’s Syndrome Market.
The Sjogren’s Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Sjogren’s Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Sjogren’s Syndrome treatment therapies with a considerable amount of success over the years.
-
Sjogren’s Syndrome companies working in the treatment market are Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others, are developing therapies for the Sjogren’s Syndrome treatment
-
Emerging Sjogren’s Syndrome therapies in the different phases of clinical trials are- R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others are expected to have a significant impact on the Sjogren’s Syndrome market in the coming years.
-
In February 2024, Johnson & Johnson (J&J) announced positive topline results for nipocalimab in treating two rare diseases: generalized myasthenia gravis (gMG) and Sjogren’s disease. These successes come after favorable results in other autoantibody-driven conditions, such as hemolytic disease of the fetus and newborn (HDFN) and rheumatoid arthritis (RA). The Phase III VIVACITY trial (NCT03772587) for nipocalimab in adults with gMG achieved its primary endpoint, showing a statistically significant reduction in daily activity score (MG-ADL) from baseline over 22 to 24 weeks compared to placebo.
-
In November 2023, Amgen released updated findings from its Phase II trial assessing dazodalibep, an experimental medication, in the management of Sjogren’s syndrome. According to the data, patients who switched from placebo to dazodalibep demonstrated an enhancement in their disease activity, showing a reduction in the total ESSDAI score from 4.1 points on Day 169 to 6.3 points on Day 365. The overall safety profile of dazodalibep appeared favorable, with the medication being well-tolerated.
Sjogren’s Syndrome Overview
Sjögren’s syndrome is a chronic autoimmune disorder that primarily affects the glands that produce saliva and tears. In this syndrome, the immune system mistakenly attacks and damages the glands, leading to a reduction in the production of saliva and tears. While it most commonly affects the salivary and lacrimal (tear) glands, it can also impact other organs and systems in the body.
Get a Free Sample PDF Report to know more about Sjogren’s Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sjogrens-syndrome-pipeline-insight
Emerging Sjogren’s Syndrome Drugs Under Different Phases of Clinical Development Include:
-
R-2487: Rise Therapeutics
-
BMS-986325: Bristol-Myers Squibb
-
RSLV-132: Resolve Therapeutics
-
CFZ533: Novartis
-
VIB4920: Horizon Therapeutics
-
VAY736: Novartis
-
Dazodalibep (VIB4920): Horizon Therapeutics (Amgen)
-
OXERVATE (cenegermin): Dompe Farmaceutici
-
Tivanisiran (SYL1001): Sylentis
-
Lusvertikimab (formerly OSE-127): OSE Immunotherapeutics/Servier
-
Nipocalimab: Johnson & Johnson
Sjogren’s Syndrome Route of Administration
Sjogren’s Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Sjogren’s Syndrome Molecule Type
Sjogren’s Syndrome Products have been categorized under various Molecule types, such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Sjogren’s Syndrome Pipeline Therapeutics Assessment
-
Sjogren’s Syndrome Assessment by Product Type
-
Sjogren’s Syndrome By Stage and Product Type
-
Sjogren’s Syndrome Assessment by Route of Administration
-
Sjogren’s Syndrome By Stage and Route of Administration
-
Sjogren’s Syndrome Assessment by Molecule Type
-
Sjogren’s Syndrome by Stage and Molecule Type
DelveInsight’s Sjogren’s Syndrome Report covers around 22+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Sjogren’s Syndrome product details are provided in the report. Download the Sjogren’s Syndrome pipeline report to learn more about the emerging Sjogren’s Syndrome therapies
Some of the key companies in the Sjogren’s Syndrome Therapeutics Market include:
Key companies developing therapies for Sjogren’s Syndrome are – Novartis, Johnson & Johnson, Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics, OSE Immunotherapeutics, Horizon Therapeutics (Amgen), Servier, and others.
Sjogren’s Syndrome Pipeline Analysis:
The Sjogren’s Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren’s Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren’s Syndrome Treatment.
-
Sjogren’s Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Sjogren’s Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren’s Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Sjogren’s Syndrome drugs and therapies
Sjogren’s Syndrome Pipeline Market Drivers
-
Increasing Prevalence, development of better Classification Criteria, increased research and development are some of the important factors that are fueling the Sjogren’s Syndrome Market.
Sjogren’s Syndrome Pipeline Market Barriers
-
However, lack of specific therapeutic approaches, limited translation of Therapies into the real world and other factors are creating obstacles in the Sjogren’s Syndrome Market growth.
Scope of Sjogren’s Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key Sjogren’s Syndrome Companies: Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others
-
Key Sjogren’s Syndrome Therapies: R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others
-
Sjogren’s Syndrome Therapeutic Assessment: Sjogren’s Syndrome current marketed and Sjogren’s Syndrome emerging therapies
-
Sjogren’s Syndrome Market Dynamics: Sjogren’s Syndrome market drivers and Sjogren’s Syndrome market barriers
Request for Sample PDF Report for Sjogren’s Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Sjogren’s Syndrome Report Introduction
2. Sjogren’s Syndrome Executive Summary
3. Sjogren’s Syndrome Overview
4. Sjogren’s Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Sjogren’s Syndrome Pipeline Therapeutics
6. Sjogren’s Syndrome Late Stage Products (Phase II/III)
7. Sjogren’s Syndrome Mid Stage Products (Phase II)
8. Sjogren’s Syndrome Early Stage Products (Phase I)
9. Sjogren’s Syndrome Preclinical Stage Products
10. Sjogren’s Syndrome Therapeutics Assessment
11. Sjogren’s Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sjogren’s Syndrome Key Companies
14. Sjogren’s Syndrome Key Products
15. Sjogren’s Syndrome Unmet Needs
16 . Sjogren’s Syndrome Market Drivers and Barriers
17. Sjogren’s Syndrome Future Perspectives and Conclusion
18. Sjogren’s Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Sjogren’s Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, by DelveInsight | Novartis, Johnson & Johnson, Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics